GlassScriptPhysician profile
Justin Mark Moore
NPI 1013178110
$1,574.95
in general payments reported to CMS, 2019-2025
17 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $26.41 · 2021: $30.88 · 2023: $15.98 · 2024: $408 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $323.56 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $295.95 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $277.38 | 2024-2025 | |
| Lilly USA, LLC | $201.72 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.44 | 2024-2025 | Caplyta |
| Pfizer INC. | $54.80 | 2025 | |
| Exact Sciences Corporation | $47.26 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Vanda Pharmaceuticals INC. | $42.69 | 2025 | Fanapt, Hetlioz |
| Abbott Laboratories | $40.29 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $36.11 | 2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.29 | 2024 | Synjardy, Tradjenta, Jardiance |
| Edwards Lifesciences Corporation | $30.85 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Glaxosmithkline, LLC. | $30.43 | 2025 | Trelegy Ellipta, Bexsero, Arexvy |
| Ucb, INC. | $24.34 | 2025 | Fintepla |
| Lundbeck LLC | $24.16 | 2025 | Rexulti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23.22 | 2025 | |
| Dexcom, INC. | $19.46 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.